Stryker to Acquire Amplitude Vascular Systems

April 13, 2026—Stryker announced that it has signed a definitive agreement to acquire Amplitude Vascular Systems, Inc. (AVS), which is a privately held company developing a next-generation intravascular lithotripsy (IVL) platform to treat calcified peripheral artery disease. Stryker stated that the acquisition is intended to strengthen its peripheral vascular (PV) portfolio by adding revascularization technology.

According to Stryker, AVS’s IVL technology uses pulsed CO₂-generated pressure waves uniformly delivered through an IVL balloon catheter to fracture calcium and optimize luminal gain. The platform is designed to enhance catheter deliverability, treatment speed, and therapy efficiency.

When it is cleared for use in applicable markets, the AVS IVL product will complement Stryker’s existing PV offerings and support the company’s strategy to expand its presence in arterial disease treatment, noted the press release.

The transaction is subject to customary closing conditions. Stryker and AVS will continue to operate as separate entities and proceed with business as usual until the transaction closes, advised Stryker.

“This acquisition represents an important step in advancing our vision to build a comprehensive peripheral vascular platform and address significant unmet clinical needs,” commented Stryker’s Chair and CEO, Kevin Lobo, in the press release. “Combining this innovation with Stryker’s scale and clinical expertise, we believe we can help expand treatment options for physicians and improve care for patients with calcified peripheral artery disease.”